Profound Medical (TSXV:PRN; OTCQX:PRFMF) closed a bought deal financing for total proceeds of $10-million.Read More
IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a second tranche of its prospectus offering of convertible debentures, raising additional proceeds of CDN $762,000.Read More
IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a previously announced prospectus offering of convertible unsecured subordinated debentures for gross proceeds of more than $6.8-million.Read More
Vital Therapies (NASDAQ:VTL) has priced a public offering of 8,750,000 newly issued common share at a price of $4 each for gross proceeds of approximately $35-million.Read More
Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has priced a public offering of 22.3 million common shares at a price of $6.75 each for gross proceeds of about $150.5 million.Read More
Arch Therapeutics (OTCQB:ARTH) priced a registered direct offering of 10,166,664 units, with each unit consisting of a common share and 0.55 of a Series F warrant, at a purchase price of 60 cents a unit for gross proceeds of about $6.1-million.Read More
3D Signatures (TSX-V:DXD) issued 5,187,618 units under a brokered private placement at a price of 75 cents a unit for gross proceeds of about $3.9-million, including a partial exercise of an over-allotment option.Read More
GeneNews (TSX:GEN) has accepted subscriptions for a non-brokered private placement offering of 9,794,203 units, at a price of 16 cents each, for proceeds of about $1.6-million.
Each unit consists of one common share and one-quarter of a warrant. Each whole warrant entitles the holder to acquire one common share at a price of 50 cents until August 15, 2018.Read More
Avivagen (TSX-V:VIV) has completed a private placement of brokered and non-brokered components, selling 60 million units for gross proceeds of $3.6-million.
Each unit consists of one common share and one-half of a warrant at a price of six cents a unit. Each whole warrant entitles the holder to acquire one common share of Avivagen at a price of nine cents for two years from closing.Read More
Titan Medical (OTCQX:TITXF; TSX:TMD) has closed a public offering of 11,670,818 units at a price of 90 cents each for gross proceeds of $10.5-million.
Each unit consists of one common share and one warrant, with each warrant exercisable to purchase an additional common shares at a price of $1 for a period of 60 months.Read More